Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

Ramaswamy Govindan; Amanda Rose Townsend; Kathy D Miller; Inderjit Mehmi; Yasutoshi Kuboki; Ecaterina Elena Dumbrava; Erika P Hamilton; Irene Vuu; Erik Rasmussen; Linda R Mileshkin; Sofia Genta; Hiroji Iwata; Sylvia Adams; Hisaki Fujii; Sant P Chawla

Conference Proceedings

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

Ramaswamy Govindan, Amanda Rose Townsend, Kathy D Miller, Inderjit Mehmi, Yasutoshi Kuboki, Ecaterina Elena Dumbrava, Erika P Hamilton, Irene Vuu, Erik Rasmussen, Linda R Mileshkin, Sofia Genta, Hiroji Iwata, Sylvia Adams, Hisaki Fujii, Sant P Chawla

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1200/JCO.2021.39.15_suppl.TPS5600

Abstract

TPS5600 Background: KIF18A is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. TP53 mutant unstable aneuploid cancer cells with chromosomal instability (CIN) features are dependent on KIF18A motor activity to prevent lethal multipolar cell division. Preclinical data demonstrate that treatment with AMG 650; an oral, first in class, selective small molecule inhibitor of KIF18A may be safe and tolerable. We are conducting a first-in-human phase 1 study with AMG 650 in adult subjects with locally advanced or metastatic solid tumors with TP53MUT, triple negative breast cancer (TNBC), high grade serous ov..

View full abstract